Roche’s PathAI acquisition follows a broader wave of investment in AI-enabled diagnostics, as the pharma giant seeks to scale digital pathology tools for precision oncology. PathAI’s platform includes image management and workflow capabilities designed to translate tissue analysis into actionable diagnostic and trial support outputs. The deal also leverages prior collaboration across companion diagnostic algorithm development, with Roche aiming to pair PathAI’s systems with Roche’s oncology diagnosis platforms. The combined approach is meant to support biomarker discovery and new diagnostic tooling across partner and internal programs. PathAI’s acquisition is expected to close in the second half of 2026, subject to customary antitrust and regulatory conditions, and is positioned as a key step to industrialize digital pathology rather than treat AI as a stand-alone research capability.